Brokers Issue Forecasts for ZVRA FY2026 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Cantor Fitzgerald issued their FY2026 earnings per share estimates for Zevra Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the company will earn $0.98 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to analysts’ expectations of $16.96 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the prior year, the business posted ($0.40) EPS.

Other equities research analysts also recently issued reports about the stock. JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim boosted their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Finally, Canaccord Genuity Group boosted their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and an average price target of $22.29.

Zevra Therapeutics Stock Down 0.1%

Shares of ZVRA opened at $9.37 on Wednesday. The company’s 50-day moving average price is $7.92 and its 200 day moving average price is $8.08. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a market cap of $512.35 million, a P/E ratio of -4.76 and a beta of 2.01.

Institutional Trading of Zevra Therapeutics

A number of large investors have recently made changes to their positions in ZVRA. Woodline Partners LP lifted its stake in Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after acquiring an additional 476,032 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock valued at $30,441,000 after purchasing an additional 3,001,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Zevra Therapeutics by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock worth $23,554,000 after purchasing an additional 68,151 shares during the last quarter. Altium Capital Management LLC lifted its position in shares of Zevra Therapeutics by 8.8% during the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock worth $15,429,000 after purchasing an additional 150,000 shares during the last quarter. Finally, AIGH Capital Management LLC grew its stake in shares of Zevra Therapeutics by 82.4% during the first quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after purchasing an additional 649,495 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director John B. Bode acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was acquired at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the purchase, the director now owns 40,000 shares of the company’s stock, valued at $318,400. This represents a 33.33% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.